New allergy shot PollenVax enters human safety testing
NCT ID NCT07317960
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This early-stage trial tests whether PollenVax, a new treatment for mugwort pollen allergy, is safe and tolerable in 30 adults aged 18 to 65. Participants receive four injections of the study drug or a placebo during the non-allergy season. The main goal is to monitor side effects and check how the body responds to the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS DUE TO ARTEMISIA POLLEN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Limited Liability Partnership "Medcenter-Rakhat"
Almaty, Almaty, 050000, Kazakhstan
Conditions
Explore the condition pages connected to this study.